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1. Breast Cancer: Challenges in
Diagnosis and Characterization Using
Molecular Imaging Techniques
At the present time, breast cancer (BC) is one of the
most frequently diagnosed cancers and the leading cause
of cancer death in females worldwide. Breast cancer is a
heterogeneous disease including different groups of illnesses
in relation to presentation, biology, clinical behavior, and
response to therapy. Thus, nowadays, knowledge of their
biology is imposed in daily practice. Likewise, we know that
tumor biology can also affect significantly the efficacy of the
different modern techniques of molecular imaging.
While many breast cancers are not associated with known
risk factors, others do, highlighting with a relative risk
[(RR) > 4] the following: females; age: >65 versus <65
years; gene mutations (BRCA1 and BRCA2); two or more
first degree relatives with BC in early ages; personal history of
BC; high breast tissue density and biopsy-confirmed atypical
hyperplasia (Breast Cancer Facts & Figures 2009-2010). In
relation with secondary prevention, we know that aspirin
and other nonsteroidal anti-inflammatory drugs (NSAIDs)
inhibit production of prostaglandins and cyclooxygenase 2,
and they are potential agents for chemoprevention of breast
cancer. A meta-analysis indicates that regular use of aspirin
may be associated with reduced risk of breast cancer (OR:
0.86) [1].
With advances in the sensitivity of mammographic scr-
eening and the broader population of women screened via
national programs in different countries, the diagnosis of
breast tumors has changed considerably. As an example,
more than 50% of all invasive breast cancers in the UK
are screen-detected and 52.3% of all invasive breast cancers
measured 15mm or less in diameter and were deemed
clinically nonpalpable [2]. Likewise, about 20–30% of the
new breast cancers are in situ carcinomas, and 60–80%
of all invasive breast cancers have no axillary lymph node
involvement (N), so we need to have new prognostic factors
other than classics ones (size, N, and distant metastases
(M)). Screening-detected breast cancer is associated with
older age, smaller tumor size, more hormone receptor
positiveness, less lymph node involvement, earlier stage,
and reduced mortality compared with symptomatic breast
cancer. According to the molecular subtype, luminal A is
the most common (63.6%) and acts as an independent
prognostic factor itself. Another aspect of practical interest
is interval cancers, those detected between two screening
scans. Interval cancer represents between 12% and 28% of
all cancers diagnosed in a screening program, especially
in women below 50 years, and have a higher percentage
of nonductal histology. Likewise, they often overexpressed
epidermal growth factor receptor (EGFR) and were more
frequently estrogen receptor negative and triple negative,
with a poorer prognosis. This observation provides new data
indicating that EGFR may be important in the etiology of
interval cancer.
The standard imaging techniques for the diagnosis of this
malignant tumor includes compression and magnification
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mammography (digital or not), breast ultrasounds (USs),
and MRI. Although PET/CT is not included in initial
explorations of breast cancer, it is known to be useful
in detecting distant metastasis (7-8% of patients who are
not suspected) and to improve the prediction of neoadju-
vant therapy response. Recently, tomosynthesis and PEM
(positron emission mammography) have been included as
diagnostic tools in a reduced number of medical centers.
The problem of imaging techniques focused on the
important number of false positive results obtained with
mammography, so reduction of false positive risk and
associated factors is, nowadays, the major goal of breast
cancer screening. Tomosynthesis has improved the diag-
nostic efficacy, and MRI can play an important role in
preoperative planning if used in selected patients with high
risk of multifocal/multicentric lesions. Also it is very useful
in young women or with dense breast and in BRCA1/2
mutation carriers. However, the histological confirmation of
all suspicious findings detected by MRI is compulsory prior
to definitive surgery [3].
2. Which ProblemsWe Find?
In daily practice, we find the following situations that require
an effort from the image scans to be solved.
2.1. Mammograms Doses of Radiation. This technique re-
quires very small doses of radiation (2–4mGy; 200–
400mRad). The risk is slight, but repeated X-rays have the
potential to cause cancer, but this is very rare. However,
we know the mechanisms of DNA repair after ionizing
radiation and many of the genes involved are altered in
certain subpopulations that we need to keep in mind. These
patients show a greater sensitivity to ionizing radiation and
the continued use of this imaging technique can be harmful.
Special interest have patients with mutations in
BRCA1and/or BRCA2 genes and ataxia telangiectasia (ATM)
gene, as well as certain genes of Fanconi anemia and those
related to the normal functioning of the cell cycle. Another
aspect of great value is the absorbed dose by the mammary
glands of girls and young women during radiological
examinations of other sites of their bodies. As an example,
the chest CT and abdominal CT scan radiate between 3 and
30 times the dose of a mammogram. We need to take into
account the future consequences of these “unnecessary”
radiations.
2.2. Occult Breast Cancer Presenting with an Axillary Metas-
tasis. Occult breast cancer incidence is decreasing, because
more primary breast cancers can be detected with the
introduction of more advanced techniques. Breast MRI can
identify the primary tumor in approximately two thirds of
this population, but, due to the low specificity, lesions need to
be histologically confirmed. Other recent imaging techniques
can be useful also. The immunohistochemical study of the
lymph node using certain breast cyst fluid proteins (alpha-2-
glycoprotein 1, zinc-binding, apolipoprotein D, GCDFP15,
etc.) may be of great diagnostic value.
2.3. Nonpalpable Breast Cancer. This is a situation of great
practical interest, and its location is a routine necessity.
There are many techniques for identification, and we know
that US-guided BCS (breast conserving surgery) could be
more accurate than wire-guide localization (WL) and ROLL-
guided surgery because it optimized the surgeon’s ability to
obtain adequate margins. However, other authors consider
that the radioguided localization surgery determines lower
positive margins rates and fewer reoperations.
2.4. Ductal Carcinoma In Situ in Younger Women. Ductal
carcinomas in situ (DCIS) are a heterogeneous entity and
early and accurate diagnosis is a necessity, since they are
often tumors in women under 40 years. Likewise, high
recurrence rates (mainly invasive: 62%; in situ: 38%) after
breast conservative treatment have been observed in young
women with this tumor.
2.5. Sentinel Node (SLNB). At present, their detection and
analysis is a mandatory practice in the breast cancer surgery.
The use of radioguided methods for lymphatic mapping
and SLNB localization has represented a breakthrough.
There are several nomograms for predicting the nonsentinel
lymph node metastases after a positive sentinel lymph node
biopsy and also we know that lymphoedema occurs in 21%
of patients who undergo axillary lymph node dissection
(ALND) versus 7% of patients who undergo SLNB. Optical
scans seem to be reliable and effective to detect this lymph
node when located in level one of the axilla. The clinical
significance of micrometastases continues to be a subject of
controversy, even though now some groups consider that
they do not influence tumor outcome.
2.6. Evaluation of Axillary LymphNodeMetastases. The accu-
rate diagnosis of axillary nodal involvement using imaging
methods is of great practical usefulness. SLNB remains the
standard of care to stage the axilla. MRI could be the most
cost-effective strategy to replace SLNB. However, further
large studies are required to obtain more accurate data on the
sensitivity and specificity of this technique [4]. Gadolinium-
enhanced MRI has a sensitivity of 88% and a specificity
of 100%, and ultrasmall superparamagnetic iron oxide-
(USPIO-) enhanced MRI has 98% and 96% respectively.
However, it does not appear that currently can replace SLNB.
Axillary ultrasound fine needle aspiration has a sensitivity
of 63.4% and a specificity of 100%, while intraoperative
frozen section analysis of the sentinel node has a sensitivity
of 76.5% and a specificity of 100%. Sensitivity of both
procedures together is 91.4%. In patients with stage II and
III breast cancer, high-resolution FDG PET/CT has reached
a sensitivity of 82% and a specificity of 92% in detecting
axillary metastases, and due to its high predictive value
(98%), if positive, SLNB may be omitted [5].
2.7. Locoregional Breast Cancer Recurrence (LRR). Luminal
tumors exhibit the lowest rates of locoregional recurrence
while patients with triple negative and HER2 overexpression
have an increased risk of developing LRR following surgery
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and other associated treatments. In this clinical situation,
FDG-PET/CT can be a good choice, with a sensitivity, speci-
ficity, accuracy, and positive and negative predictive values of
97%, 92%, 95%, and 94% and 96%, respectively. Also, this
technique can change the clinical management in almost half
of the patients. The use of new PET tracers opens a new point
of view giving us more physiopathological information. Also
the “classic” imaging techniques (mammography US), MRI,
and PEM can play an important role is this clinical situation.
2.8. Identification of Residual Breast Tumor Localization
after Neoadjuvant Chemotherapy. It is an increasing clinical
situation due to the enhancing of conservative surgery.
Besides the current imaging techniques, recently has been
introduced in clinical practice the use of 125I seed and its
injection into the tumor area before chemotherapy with very
good results, due to the half time of 125I (60 days).
3. Challenges
The first challenge posed is to diagnose and establish the stage
of breast cancer in its earliest stages and as safely as possible.
Also the study of premalignant lesions will be crucial in the
near future. We must focus our efforts in these different
areas to make no delay diagnosis. In relation with this, in
Sweden, the delay in diagnosis occurs in about 1/1000 new
patients and the delay was considered to have an impact on
the magnitude of therapeutic measures in almost 25% of the
women. Economic compensation for the patient’s injuries
was given in 90% of the cases [6]. The second challenge is
the detection of a recurrence prior to the development of
symptoms, which can improve overall survival. The third
challenge will be to study how the biology of the tumor
is capable of influence imaging techniques, especially the
molecular imagines, and how we define those targets that
allow us the biological characterization of an injury through
an image. The use of modern laboratory techniques (stem
cells, proteomics, epigenetic, etc.) will be mandatory. The use
of advance imaging technology is a necessity and a reality,
but, as Panageas et al. write [7], a question arises in some
situations: “It is not clear whether if early detection of distant
recurrence leads to a survival benefit improvement or whether
it simply increases the amount of time women spend living with
the knowledge that their disease has recurred.”
Finally, we thank the different authors for their hard
work and excellent papers that allowed the elaboration of this
special issue. Our main goal was to show different aspects
of breast cancer related to biology and molecular imaging as
well as their clinical usefulness.
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